Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
At the recent annual meeting of the Austrian Working Group for Gynaecological Oncology in the Austrian Society for Gynecology and Obstetrics the Ernst Wertheim Award was presented to Dr Marie Plante, the CCTG CX5 study lead and Gynecologic Oncologist at CHU de Quebec, Canada.
CCTG has been working closely with our NCI/CTSU counterparts to develop the process and workflow for investigator and research staff registrations. Here is what is understood as we move toward implementation:
1. All individuals that are registered at the time of the changeover will be grandfathered.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative volunteer for the Investigational New Drug (IND) Committee.
CCTG is excited to extend our congratulations to Dr. Lillian Siu who was recently announced as the 2024 ASCO David Karnofsky Memorial Award winner. The award and lecture are presented during the upcoming ASCO Annual Meeting in honor of outstanding contributions to the research, in the diagnosis and treatment of cancer.
The CCTG Annual Spring Meeting is only 4 weeks away
All meeting information is available on the Spring Meeting Web Page and includes:
Meeting Invitation - Important deadlines
